Biotechnology - Takeda Pharmaceuticals

Filter

Current filters:

Takeda Pharmaceuticals

Popular Filters

Mersana in deal with Takeda to develop ADCs

Mersana in deal with Takeda to develop ADCs

07-04-2014

Privately-held US biotech firm Mersana Therapeutics has entered into a collaboration agreement with Japanese…

Antibody-drug conjugateBiotechnologyBusiness FinanceHealth Medical PharmaHealth Medical PharmaLicensingMajorMersana TherapeuticsMillennium PharmaceuticalsOncologyResearchTakeda Pharmaceuticals

Modest growth forecast for global Crohn’s disease market

Modest growth forecast for global Crohn’s disease market

04-02-2014

The global Crohn’s disease (CD) market value is forecast to show modest growth, climbing from $3.2…

AbbVieBiotechnologyEntyvioGastro-intestinalsGlobalHumiraJohnson & JohnsonMarkets & MarketingPharmaceuticalRemicadeStelara InjectionTakeda Pharmaceuticals

Modest growth seen for MAbs market for colorectal cancer, as late-stage pipeline is weak

14-12-2013

The market value for monoclonal antibodies in colorectal cancer treatment will experience a moderate…

AvastinBiotechnologyBristol-Myers SquibbErbituxMarkets & MarketingMerck KGaAOncologyResearchRocheTakeda PharmaceuticalsVectibix

Further highlights from European Society of Cardiology meeting

03-09-2013

The ongoing European Society of Cardiology meeting in Amsterdam, Netherlands, continues to produce both…

ActelionalogliptinAmgenBiotechnologyCardio-vascularCytokineticsDiabetesomecamtiv mecarbilOpsumitPharmaceuticalResearchRespiratory and PulmonaryTakeda Pharmaceuticals

Regulatory briefs: Sanofi's Fluzone; Roche' RoActemra; Takeda's Rienso

10-06-2013

French pharma major Sanofi (Euronext: SAN) today (June 10) announced that the US Food and Drug Administration…

Anti-Arthritics/RheumaticsBiotechnologyPharmaceuticalRegulationRocheSanofiTakeda PharmaceuticalsVaccines

Infinity amends PI3K-delta, gamma accord with Millennium

28-12-2012

US drug discovery firm Infinity Pharmaceuticals (Nasdaq: INFI) says it has amended its development and…

BiotechnologyFinancialInfinity PharmaceuticalsIPI-145LicensingMillennium PharmaceuticalsPharmaceuticalRespiratory and PulmonaryTakeda Pharmaceuticals

Pain therapies sales to exceed $49 billion in 2026, driven by new product launches

16-12-2012

The market for pain therapies will grow at an annual rate of 1.8% over the next 15 years, surpassing…

BiotechnologyfulranumabGlobalJohnson & JohnsonMarkets & MarketingNeurologicalPfizerPharmaceuticalTakeda Pharmaceuticalstanezumabtapentadol

FDA grants Seattle Genetics' Adcetris orphan rating in MF

27-11-2012

US biotech firm Seattle Genetics (Nasdaq: SGEN) says its Adcetris (brentuximab vedotin) has been granted…

AdcetrisBiotechnologyNorth AmericaOncologyPharmaceuticalRegulationSeattle GeneticsTakeda Pharmaceuticals

European Commission grants conditional approval for Adcetris

01-11-2012

Millennium, a wholly owned subsidiary of Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502)…

AdcetrisBiotechnologyEuropeMillennium PharmaceuticalsOncologyPharmaceuticalRegulationSeattle GeneticsTakeda Pharmaceuticals

Multiple myeloma drug market forecast to reach $7.2 billion in 2021

03-10-2012

The multiple myeloma drug market will experience significant growth, increasing from $4.4 billion in…

BiotechnologyCelgeneGlobalJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalRevlimidTakeda PharmaceuticalsVelcade

Briefs: Takeda and Lundbeck file vortioxetine NDA; Merck Serono spin-out

03-10-2012

Japan's biggest drugmaker Takeda Pharmaceutical (TYO: 4502) and partner Danish CNS specialist Lundbeck…

AsceneurionBiotechnologyLundbeckMerck KGaAMerck SeronoMergers & AcquisitionsNeurologicalPharmaceuticalRegulationTakeda Pharmaceuticalsvortioxetine

CHMP positive on first gene therapy, Glybera; and more opinions

23-07-2012

Reversing an earlier negative opinion (The Pharma Letter April 22), the European Medicines Agency's Committee…

AdcetrisBiotechnologyCelgeneDacogenEuropeGlyberaIstodaxJanssen-CilagJohnson & JohnsonOncologyPfizerPharmaceuticalRare diseasesRegulationTakeda PharmaceuticalsuniQureXalkori

Amylin said to be attracting several Big Pharma suitors

16-05-2012

US biotech firm Amylin Pharmaceuticals (Nasdaq: AMLN), which earlier this year rebuffed a $22 per share…

AmylinAstraZenecaBiotechnologyBristol-Myers SquibbMerck & CoMergers & AcquisitionsPfizerPharmaceuticalRocheSanofiTakeda Pharmaceuticals

Affymax and Takeda get special Medicare code for Omontys

16-04-2012

USA-based Affymax (Nasdaq: AFFY) and the US subsidiary of Japanese drug major Takeda Pharmaceuticals…

AffymaxBiotechnologyNephrology and HepatologyNorth AmericaOmontysOncologypeginesatidePharmaceuticalPricingRegulationTakeda Pharmaceuticals

FDA backs Affymax and Takeda drug Omontys for anemia due to CKD

28-03-2012

The US Food and Drug Administration yesterday approved Omontys (peginesatide, formerly known as Hematide)…

AffymaxBiotechnologyNephrology and HepatologyNorth AmericaOmontyspeginesatidePharmaceuticalRegulationTakeda Pharmaceuticals

Back to top